February 26, 2026 02:41 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
India-US trade deal at risk? Trump imposes massive 126% duty on solar imports | ‘My life reflects this reality’: Shooter Tara Shahdeo recalls forced conversion amid Kerala Story 2 row | Modi begins Israel visit to boost defence, tech and strategic ties | Trump claims Pakistan PM told him he prevented 35 million deaths by stopping India-Pakistan conflict | Supreme Court's big move over Bengal SIR! Odisha, Jharkhand judicial officers allowed to complete revision process | ‘Kerala lives in harmony, film’s portrayal wrong’: Kerala High Court raps Kerala Story sequel makers | AI panic hits IT giants: Infosys, TCS, Wipro lead massive market rout as stocks sink to alarming lows | ‘No systemic risk’: Sanjay Malhotra breaks silence on ₹590 crore IDFC First Bank Limited fraud | India urges all nationals to leave Iran 'by available means' as US-Iran tension grows | India shines at BAFTA! All you need to know about Manipuri film Boong that stunned global cinema
Pregnancy
Pixabay

U.S. FDA approves first nonprescription daily oral contraceptive

| @indiablooms | Jul 14, 2023, at 03:30 pm

Los Angeles: The U.S. Food and Drug Administration (FDA) on Thursday approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy, which is the first daily oral contraceptive approved for use in the United States without a prescription.

Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stores, convenience stores and grocery stores, as well as online.

Nonprescription availability of Opill may reduce barriers to access by allowing individuals to obtain an oral contraceptive without the need to first see a health care provider, said the FDA in a statement.

The most common side effects of Opill include irregular bleeding, headaches, dizziness, nausea, increased appetite, abdominal pain, cramps or bloating, according to the FDA.

"Today's approval marks the first time a nonprescription daily oral contraceptive will be an available option for millions of people in the United States," said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.